A randomized, open-label, parallel-design, multicenter, Phase III study to compare the safety and efficacy of a fixed dose combination of SULBACTOMAX Vs CEFTRIAXONE in the treatment of hospitalized adult patients with Community-Acquired Pneumonia
100 Clinical Results associated with KOREA PHARMA Co., Ltd.
0 Patents (Medical) associated with KOREA PHARMA Co., Ltd.
100 Deals associated with KOREA PHARMA Co., Ltd.
100 Translational Medicine associated with KOREA PHARMA Co., Ltd.